Neumega (Oprelvekin) has been approved to promote the production of the body's supply of platelets in cancer patients with solid tumors or lymphoma who are undergoing chemotherapy. By significantly reducing the incidence of severely low platelet levels (thrombocytopenia), a serious side effect which often delays chemotherapy administration, Neumega may give some cancer patients a better chance of receiving the treatment they need to fight their disease.
In clinical trial involving 170 patients, Neumega reduced the incidence of severe chemotherapy-induced platelet depletion, reduced the need for platelet transfusions, and reduced the number of platelet transfusions required.
The most common adverse effects associated with Neumega treatment included peripheral edema, dyspnea, tachycardia, and conjunctival redness.
The Neumega drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.